摘要
慢性HBV感染免疫控制期患者肝脏一般无损伤,不良事件发生率低,部分患者可以发生HBsAg自然阴转,国内外大多数学者对该期患者通常不推荐抗病毒治疗。然而随着慢性HBV感染逐渐进入老龄化,此期患者同样面临着不同程度的疾病进展以及肝硬化、肝癌的发生。介绍了对于慢性HBV感染免疫控制期患者,把握合适的抗病毒治疗时机对其预后的临床意义。
Patients with chronic hepatitis B virus(HBV)infection with immune control generally have no or little liver damage,with a low incidence rate of adverse events,and spontaneous HBsAg seroclearance may occur in some patients.Most scholars do not recommend antiviral therapy for such patients in China and foreign countries.However,with the gradual aging of chronic HBV infection,patients with immune control are also faced with disease progression and the development of liver cirrhosis or liver cancer.This article introduces the clinical significance of appropriate timing of antiviral therapy for the prognosis of patients with chronic HBV infection with immune control.
作者
周路路
刘娜
李春霞
东冰
张楠
任丹丹
徐光华
ZHOU Lulu;LIU Na;LI Chunxia(Department of Infectious Diseases, Affiliated Hospital of Yan’an University, Yan’an, Shaanxi 716000, China)
出处
《临床肝胆病杂志》
CAS
北大核心
2020年第5期1134-1137,共4页
Journal of Clinical Hepatology
基金
延安市惠民计划项目(HM2009-04)。
关键词
乙型肝炎
慢性
免疫控制期
诊断
治疗学
hepatitis B,chronic
immune control
diagnosis
therapeutics
